Logo

Good News, and a Blast from the Past

Dec 19, 2007

Sure, it's probably been a long time since you've thought about Human Genome Sciences. But Venter's former business partner just announced positive results of its anthrax drug in animal studies, reports this article in the Wall Street Journal. The company said that "a single dose of its anthrax-fighting drug ABthrax -- without benefit of any additional antibiotics -- improved survival rates from inhalation of deadly anthrax spores by up to 64% in test subjects," according to the article.

 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.